Magnesiumsulfat B. Braun (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as cofactors for enzymatic reactions, compete with calcium at voltage‑gated channels, stabilize neuronal membranes, cause vasodilation, and relax smooth muscle. These actions correct electrolyte deficits, reduce neuronal excitability, and help normalize cardiac rhythm.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, serum magnesium level, renal function, and clinical response. Dosing regimens are individualized and should follow the prescriber’s order.

Safety data in pregnancy are limited; the product should be used only when the expected benefit to the mother outweighs any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as magnesium can be excreted in breast milk.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Magnesium sulfate is the most widely used injectable magnesium salt because of its high solubility and rapid bioavailability. Compared with oral magnesium oxide or gluconate, the sulfate form achieves faster serum level correction, which is essential in acute settings such as eclampsia or severe arrhythmias.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

Magnesiumsulfat B. Braun is supplied as a sterile solution for intramuscular or intravenous injection. Administration routes, infusion rates, and dilution volumes are determined by the treating clinician and should follow institutional protocols and the product’s prescribing information.

Serious risks include hypermagnesemia leading to respiratory depression, cardiac arrest, severe hypotension, and anaphylactic reactions. Monitoring of serum magnesium, blood pressure, respiratory status and cardiac rhythm is essential, especially in patients with renal impairment or when combined with other depressant agents.

Patients with severe renal failure, known hypersensitivity to magnesium sulfate, or those receiving high‑dose calcium channel blockers or neuromuscular blocking agents without appropriate monitoring should avoid this product unless a clinician determines that benefits outweigh risks.